PVG Asset Management’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-53,125
| Closed | -$215K | – | 62 |
|
|
2025
Q1 | $215K | Sell |
53,125
-70,350
| -57% | -$234K | 0.93% | 33 |
|
|
2024
Q4 | $395K | Sell |
123,475
-26,395
| -18% | -$89.5K | 1.87% | 22 |
|
|
2024
Q3 | $336K | Buy |
149,870
+12,676
| +9% | +$29.3K | 1.35% | 27 |
|
|
2024
Q2 | $295K | Buy |
+137,194
| New | +$244K | 1.17% | 22 |
|
|
2023
Q4 | $264K | Buy |
115,372
+4,347
| +4% | +$9.46K | 1.28% | 18 |
|
|
2023
Q3 | $189K | Buy |
111,025
+50,000
| +82% | +$114K | 1.29% | 20 |
|
|
2023
Q2 | $151K | Sell |
61,025
-76,227
| -56% | -$208K | 0.65% | 29 |
|
|
2023
Q1 | $309K | Buy |
137,252
+82,269
| +150% | +$413K | 0.99% | 17 |
|
|
2022
Q4 | $281K | Buy |
54,983
+15,745
| +40% | +$113K | 1.24% | 25 |
|
|
2022
Q3 | $408K | Buy |
+39,238
| New | +$468K | 1.58% | 12 |
|
|
2021
Q4 | $250K | Sell |
8,031
-882
| -10% | -$29.2K | 0.91% | 26 |
|
|
2021
Q3 | $294K | Buy |
8,913
+6,402
| +255% | +$189K | 0.88% | 26 |
|
|
2021
Q2 | $74.1K | Buy |
2,511
+1,024
| +69% | +$28.4K | 0.23% | 49 |
|
|
2021
Q1 | $46.7K | Buy |
+1,487
| New | +$49.8K | 0.15% | 42 |
|
PVG Asset Management's CKPT Position: Q2 2025 in Review
PVG Asset Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 53,125 shares — an estimated $215K sold.
PVG Asset Management first reported a position in CKPT in Q1 2021 and held it in 14 quarters. The position peaked at $408K in Q3 2022. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- PVG Asset Management reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- PVG Asset Management sold 53,125 Checkpoint Therapeutics shares in Q2 2025, an estimated $215K.
- PVG Asset Management first reported a position in Checkpoint Therapeutics in Q1 2021 and held it in 14 quarters.
- PVG Asset Management's Checkpoint Therapeutics position peaked at $408K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on PVG Asset Management's 13F filing for Q2 2025, filed 2 Sep 2025.